As facial, scalp, and body hair are closely linked to gender expression and perception, hair concerns represent important considerations in gender minority patients. Diagnosis and subsequent treatment of hair conditions in this population require an understanding of gender affirming hormones, which include both masculinizing hormone therapy (MHT, i.e. testosterone use) and feminizing hormone therapy (FHT, i.e. estrogen and antiandrogen use).¹ Testosterone has been found to induce androgenetic alopecia (AGA) in roughly two‐thirds of transmen, while estrogen/antiandrogens have been shown to increase scalp hair density in transwomen in limited case reports.2,3 In this cross‐sectional study, we sought to capture the frequency of scalp hair loss and its relation to gender affirming hormone use in gender minority patients.
This article is protected by copyright. All rights reserved.